Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study
Authors:
- Max BeugelingMBMax Beugeling
- Katie AmssomsKAKatie Amssoms
- Freek CoxFCFreek Cox
- Ben De ClerckBCBen De Clerck
- Ellen Van GulckEGEllen Van Gulck
- Jeroen A. VerwoerdJVJeroen A. Verwoerd
- Guenter KrausGKGuenter Kraus
- Dirk RoymansDRDirk Roymans
- Lieven BaertLBLieven Baert
- Henderik W. FrijlinkHFHenderik W. Frijlink
- Wouter L. J. HinrichsWouter L. J. Hinrichs
Open Access
- 3 October 2019
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (10) , 510
Abstract
Currently, there is an increasing interest to apply pre-fusion (pre-F) protein of respiratory syncytial virus (RSV) as antigen for the development of a subunit vaccine. A pre-F-containing powder would increase the flexibility regarding the route of administration. For instance, a pre-F-containing powder could be incorporated into a single-injection system releasing a primer, and after a lag time, a booster. The most challenging aspect, obtaining the booster after a lag time, may be achieved by incorporating the powder into a core encapsulated by a nonporous poly(dl-lactic-co-glycolic acid) (PLGA) shell. We intended to develop a stable freeze-dried pre-F-containing powder. Furthermore, we investigated whether incorporation of this powder into the core-shell implant was feasible and whether this system would induce a delayed RSV virus-neutralizing antibody (VNA) response in mice. The developed pre-F-containing powder, consisting of pre-F in a matrix of inulin, HEPES, sodium chloride, and Tween 80, was stable during freeze-drying and storage for at least 28 days at 60 °C. Incorporation of this powder into the core-shell implant was feasible and the core-shell production process did not affect the stability of pre-F. An in vitro release study showed that pre-F was incompletely released from the core-shell implant after a lag time of 4 weeks. The incomplete release may be the result of pre-F instability within the core-shell implant during the lag time and requires further research. Mice subcutaneously immunized with a pre-F-containing core-shell implant showed a delayed RSV VNA response that corresponded with pre-F release from the core-shell implant after a lag time of approximately 4 weeks. Moreover, pre-F-containing core-shell implants were able to boost RSV VNA titers of primed mice after a lag time of 4 weeks. These findings could contribute to the development of a single-injection pre-F-based vaccine containing a primer and a booster.Keywords
This publication has 39 references indexed in Scilit:
- Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccinesBiotechnology Advances, 2017
- Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta–analysisJournal of Global Health, 2015
- Single-injection vaccines: Progress, challenges, and opportunitiesJournal of Controlled Release, 2015
- Simplifying Influenza Vaccination During Pandemics: Sublingual Priming and Intramuscular Boosting of Immune Responses with Heterologous Whole Inactivated Influenza VaccineThe AAPS Journal, 2014
- Interdependency of protein-release completeness and polymer degradation in PLGA-based implantsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2013
- Respiratory Syncytial Virus–Associated Hospitalizations Among Children Less Than 24 Months of AgePediatrics, 2013
- Mapping Microclimate pH Distribution inside Protein-Encapsulated PLGA Microspheres Using Confocal Laser Scanning MicroscopyMolecular Pharmaceutics, 2012
- Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical interventionProceedings of the National Academy of Sciences, 2012
- Protein Instability in Poly(Lactic-co-Glycolic Acid) MicroparticlesPharmaceutical Research, 2000
- Single-administration vaccines: controlled-release technology to mimic repeated immunizationsTrends in Biotechnology, 1999